REGENXBIO (RGNX) director Kenneth Mills granted RSUs and 46,600 stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

REGENXBIO Inc. director Kenneth T. Mills reported equity awards consisting of restricted stock units and stock options. On May 29, 2026, he received 9,807 shares of common stock through a time-based restricted stock unit award that carries no cash exercise price. These RSUs are scheduled to vest 100% on May 29, 2027, conditioned on his continuous service to the company. On the same date, he was also granted stock options covering 46,600 shares of common stock at an exercise price of $7.01 per share, which are likewise scheduled to vest on May 29, 2027, subject to continued service. Following the stock grant, Mills directly held 495,925 shares of REGENXBIO common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Mills Kenneth T.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	46,600	$0.00	--
Grant/Award	Common Stock	9,807	$0.00	--

Holdings After Transaction: Stock Options (Right to Buy) — 46,600 shares (Direct, null); Common Stock — 495,925 shares (Direct, null)

Footnotes (1)

Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. The option will vest May 29, 2027 subject to the continuous service of the optionee to the Issuer.

Key Figures

RSU shares granted: 9,807 shares Options granted: 46,600 options Option exercise price: $7.01 per share +4 more

7 metrics

RSU shares granted 9,807 shares Time-based RSU award granted May 29, 2026

Options granted 46,600 options Stock options granted May 29, 2026

Option exercise price $7.01 per share Strike price for 46,600 stock options

Shares held after grant 495,925 shares Common stock directly owned after RSU grant

RSU vesting date May 29, 2027 100% vesting for 9,807 RSU shares

Option vesting date May 29, 2027 Vesting date for 46,600 stock options

Option expiration May 29, 2036 Expiration date of granted stock options

Key Terms

restricted stock unit, time-based, Stock Options (Right to Buy), exercise price, +1 more

5 terms

restricted stock unit financial

"Represents shares of common stock underlying a time-based restricted stock unit award (RSU)."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

time-based financial

"Represents shares of common stock underlying a time-based restricted stock unit award (RSU)."

Stock Options (Right to Buy) financial

"Stock Options (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: "7.0100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

continuous service financial

"subject to the continuous service of the recipient to the Issuer."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/02/2026 - 05:16 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mills Kenneth T.

(Last)

(First)

(Middle)

C/O REGENXBIO INC.

9804 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE

MARYLAND

20850

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENXBIO Inc. [ RGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/29/2026		A		9,807⁽¹⁾	A	$0.00	495,925	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)	$7.01	05/29/2026		A		46,600		05/29/2027⁽²⁾	05/29/2036	Common Stock	46,600	$0.00	46,600	D

Explanation of Responses:

1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.

2. The option will vest May 29, 2027 subject to the continuous service of the optionee to the Issuer.

Remarks:

	/s/ Patrick J. Christmas as attorney-in-fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did REGENXBIO (RGNX) director Kenneth Mills report?

Kenneth T. Mills reported equity awards, not open-market trades. He received 9,807 restricted stock units and stock options for 46,600 shares, both granted on May 29, 2026 as part of his compensation package.

How many REGENXBIO (RGNX) shares does Kenneth Mills hold after this Form 4?

After the reported grant, Kenneth T. Mills directly holds 495,925 shares of REGENXBIO common stock. This figure reflects his position following receipt of 9,807 time-based restricted stock units reported in the filing.

What are the vesting terms of Kenneth Mills’ RSU award at REGENXBIO (RGNX)?

The RSU award covers 9,807 shares of common stock and vests 100% on May 29, 2027. Vesting is conditioned on Kenneth T. Mills’ continuous service to REGENXBIO through that date, according to the filing footnote.

What are the details of the stock options granted to Kenneth Mills by REGENXBIO (RGNX)?

Mills received stock options for 46,600 shares of common stock at a $7.01 exercise price. These options are scheduled to vest on May 29, 2027, provided he continues serving the company through that vesting date.

Did Kenneth Mills buy or sell REGENXBIO (RGNX) shares on the open market?

No open-market buys or sells were reported. The Form 4 shows grant or award acquisitions only: time-based restricted stock units and stock options issued as compensation, with no cash purchase or sale of existing shares disclosed.